Agenus Poised for Breakthrough with Upcoming Clinical Data
AI Prediction of Agenus Inc. (AGEN)
Agenus Inc. is poised for a significant potential breakthrough with its lead assets botensilimab and balstilimab in the treatment of metastatic colorectal cancer, with upcoming clinical data presentations that could catalyze its stock price.
Agenus Inc., a clinical-stage biotechnology company, focuses on immuno-oncology treatments with its leading candidates botensilimab and balstilimab. These drugs are currently in late-stage clinical trials for metastatic colorectal cancer (mCRC), a market with significant unmet needs. The company is expected to present crucial data at the upcoming AACR 2026 event on April 21, which could substantially impact its valuation and market position. A positive outcome could validate the efficacy of its treatment regimen, potentially leading to accelerated approval and commercialization. This event serves as a critical inflection point for Agenus, offering significant upside potential for investors if the results are favorable.
AGEN Report Information
Prediction Date2026-03-25
Close @ Prediction$3.56
Mkt Cap145m
IPO DateN/a
AI-derived Information
Recent News for AGEN
- May 21, 5:00 pm — Agenus and Noetik Present ASCO 2026 Data Linking AI Analysis of Routine Pretreatment Tumor Pathology Images to Response and Survival with BOT+BAL in MSS Metastatic CRC (Business Wire)
- May 21, 5:00 pm — Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026 (Business Wire)
- May 15, 4:11 pm — Agenus Announces Publication of Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Hepatocellular Carcinoma in Liver Cancer (Business Wire)
- May 11, 5:27 pm — Agenus: Q1 Earnings Snapshot (Associated Press)
- May 11, 8:45 am — Agenus Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Global Access and Phase 3 Development (Business Wire)
- May 4, 4:30 pm — Agenus to Provide First Quarter 2026 Financial Report and Corporate Update (Business Wire)
- Apr 21, 10:00 am — Agenus to Present First Phase 2 Botensilimab Data in Advanced Cutaneous Melanoma at ASCO 2026 (Business Wire)
- Apr 21, 8:00 am — Agenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access Programs (Business Wire)
- Apr 17, 4:43 pm — Agenus Reports Phase II Data Demonstrating Immune Reprogramming and Durable Survival with Botensilimab, Balstilimab and agenT-797 in PD-1 Refractory Gastroesophageal Cancer (Business Wire)
- Apr 3, 7:30 am — Agenus Announces Data from Phase II Study of BOT+BAL in Combination with agent-797 in PD-1 Refractory Gastroesophageal Cancer to be Presented at AACR 2026 (Business Wire)
- Apr 1, 7:30 am — Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer (Business Wire)
- Mar 26, 4:52 pm — Agenus to Host March 2026 Stakeholder Webcast Harnessing the Immune System to Advance BOT + BAL Across Tumor Types and Expand Patient Access (Business Wire)
Welcome to ScanScor. What you're reading is no ordinary summary -- it's the result of a carefully-crafted interactive session with OpenAI's most advanced models crafted from news, trial details, and financial data. This report attempts to maximize the potential for OpenAI's smartest GPT-based analysis engine, guided by tightly structured prompts to expose the forces behind today's market movers and to predict the future.
Disclaimer: This report is for informational purposes only. It does not constitute financial advice. Always do your own research before making any investment.
Subscribe
Login
Please login to comment
0 Comments
Oldest